Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 584

1.

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.

Allum WH, Smyth EC, Blazeby JM, Grabsch HI, Griffin SM, Rowley S, Cafferty FH, Langley RE, Cunningham D.

Br J Surg. 2019 Aug;106(9):1204-1215. doi: 10.1002/bjs.11184. Epub 2019 Jul 3.

PMID:
31268180
2.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

Smyth EC, Rowley S, Cafferty FH, Allum W, Grabsch HI, Stenning S, Wotherspoon A, Alderson D, Crosby T, Mansoor W, Waters JS, Neville-Webbe H, Darby S, Dent J, Seymour M, Thompson J, Sothi S, Blazeby J, Langley RE, Cunningham D.

JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1179. [Epub ahead of print]

3.

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

Schiavone F, Bathia R, Letchemanan K, Masters L, Amos C, Bara A, Brown L, Gilson C, Pugh C, Atako N, Hudson F, Parmar M, Langley R, Kaplan RS, Parker C, Attard G, Clarke NW, Gillessen S, James ND, Maughan T, Sydes MR; past and present members of the STAMPEDE and FOCUS4 Trial Management Group.

Trials. 2019 May 29;20(1):264. doi: 10.1186/s13063-019-3216-8.

4.

Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.

Lebwohl M, Langley RG, Zhu Y, Zhou H, Song M, Shen YK, Parnell Lafferty K, Reich K.

J Eur Acad Dermatol Venereol. 2019 May 11. doi: 10.1111/jdv.15668. [Epub ahead of print]

PMID:
31077471
5.

Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression.

Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC Jr.

Cancers (Basel). 2019 Apr 30;11(5). pii: E603. doi: 10.3390/cancers11050603.

6.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.

J Eur Acad Dermatol Venereol. 2019 Apr 22. doi: 10.1111/jdv.15637. [Epub ahead of print]

PMID:
31009130
7.

Response variance prediction using transient statistical energy analysis.

Langley RS, Hawes DH, Butlin T, Ishii Y.

J Acoust Soc Am. 2019 Feb;145(2):1088. doi: 10.1121/1.5090501.

PMID:
30823815
8.

In utero ultrafine particulate matter exposure causes offspring pulmonary immunosuppression.

Rychlik KA, Secrest JR, Lau C, Pulczinski J, Zamora ML, Leal J, Langley R, Myatt LG, Raju M, Chang RC, Li Y, Golding MC, Rodrigues-Hoffmann A, Molina MJ, Zhang R, Johnson NM.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3443-3448. doi: 10.1073/pnas.1816103116. Epub 2019 Feb 11.

9.

Targeting growth hormone function: strategies and therapeutic applications.

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK.

Signal Transduct Target Ther. 2019 Feb 8;4:3. doi: 10.1038/s41392-019-0036-y. eCollection 2019. Review.

10.

Risk Assessment and Recommendations for Forester Exposure to Hymenoptera.

Dillane D, Richards SL, Balanay JAG, Langley R.

J Agromedicine. 2019 Apr;24(2):146-156. doi: 10.1080/1059924X.2019.1567425. Epub 2019 Jan 29.

PMID:
30624160
11.

Macrolides and mycobacterium abscessus abscessus: A good idea?

Langley RJ, Urquhart DS.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):394. doi: 10.4103/ijmy.ijmy_127_18. No abstract available.

12.

Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.

Gilbert DC, Wakeham K, Langley RE, Vale CL.

Br J Cancer. 2019 Jan;120(2):256-268. doi: 10.1038/s41416-018-0273-9. Epub 2018 Nov 28.

PMID:
30482913
13.

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A.

Ann Oncol. 2018 Dec 1;29(12):2356-2362. doi: 10.1093/annonc/mdy407.

14.

Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsis.

Duplessis C, Gregory M, Frey K, Bell M, Truong L, Schully K, Lawler J, Langley RJ, Kingsmore SF, Woods CW, Rivers EP, Jaehne AK, Quackenbush EB, Fowler VG, Tsalik EL, Clark D.

J Intensive Care. 2018 Nov 13;6:72. doi: 10.1186/s40560-018-0341-5. eCollection 2018.

15.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

16.

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.

Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R.

Br J Dermatol. 2019 Feb;180(2):306-314. doi: 10.1111/bjd.17318. Epub 2018 Dec 27.

PMID:
30328108
17.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.

PMID:
30198588
18.

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2126-2133. doi: 10.1111/jdv.15203. Epub 2018 Aug 28.

PMID:
30067882
19.

Photokeratitis among restaurant workers: A case series.

Stripp MP, Dulaney AR, Beuhler MC, Langley RL.

Am J Ind Med. 2018 Jul 11. doi: 10.1002/ajim.22875. [Epub ahead of print]

PMID:
29998493
20.

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.

Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J Jr.

Br J Dermatol. 2018 Nov;179(5):1205-1207. doi: 10.1111/bjd.16901. Epub 2018 Sep 11. No abstract available.

PMID:
29927479
21.

Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.

Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, Wolk R, Valdez H, Rottinghaus S, Tallman A, Gupta P.

Clin Pharmacol Drug Dev. 2018 Aug;7(6):587-596. doi: 10.1002/cpdd.471. Epub 2018 Jun 1.

PMID:
29856518
22.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 Jul 2;128(7):3199. doi: 10.1172/JCI122301. Epub 2018 May 29. No abstract available.

23.

The direction of travel to better outcomes for patients with oesophago-gastric cancer.

Langley RE.

J Thorac Dis. 2018 Mar;10(3):1236-1238. doi: 10.21037/jtd.2018.03.23. No abstract available.

24.

Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.

Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI.

Eur J Cancer. 2018 May;94:104-114. doi: 10.1016/j.ejca.2018.02.014. Epub 2018 Mar 20.

25.

Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters.

Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, Bermejo-Martin JF, Almansa R, Tamayo E, Howrylak JA, Choi A, Parnell GP, Tang B, Nichols M, Woods CW, Ginsburg GS, Kingsmore SF, Omberg L, Mangravite LM, Wong HR, Tsalik EL, Langley RJ, Khatri P.

Crit Care Med. 2018 Jun;46(6):915-925. doi: 10.1097/CCM.0000000000003084.

26.

Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin.

Walker J, Hutchison P, Ge J, Zhao D, Wang Y, Rothwell PM, Gaziano JM, Chan A, Burn J, Chia J, Langley R, O'Donnell V, Rocca B, Hawkey C.

Ecancermedicalscience. 2018 Feb 20;12:813. doi: 10.3332/ecancer.2018.813. eCollection 2018.

27.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.

PMID:
29488226
28.

Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.

Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI.

Histopathology. 2018 Jun;72(7):1180-1188. doi: 10.1111/his.13491. Epub 2018 Mar 25.

29.

A community approach to mortality prediction in sepsis via gene expression analysis.

Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, Bermejo-Martin JF, Almansa R, Tamayo E, Davenport EE, Burnham KL, Hinds CJ, Knight JC, Woods CW, Kingsmore SF, Ginsburg GS, Wong HR, Parnell GP, Tang B, Moldawer LL, Moore FE, Omberg L, Khatri P, Tsalik EL, Mangravite LM, Langley RJ.

Nat Commun. 2018 Feb 15;9(1):694. doi: 10.1038/s41467-018-03078-2.

30.

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).

Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators.

Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15.

PMID:
29405255
31.

Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.

Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, James N, Langley R, Parmar M; STAMPEDE and PATCH Trial Management Groups.

BJU Int. 2018 May;121(5):680-683. doi: 10.1111/bju.14153. Epub 2018 Feb 28. No abstract available.

32.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
33.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.

Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):17-32. doi: 10.1007/s13555-017-0211-4. Epub 2017 Dec 7.

34.

Neoadjuvant chemotherapy in oesophageal adenocarcinoma - Authors' reply.

Alderson D, Nankivell M, Langley R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):e641. doi: 10.1016/S1470-2045(17)30776-3. Epub 2017 Oct 31. No abstract available.

PMID:
29208395
35.

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.

Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A.

Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1.

PMID:
29171861
36.

Multi-arm Clinical Trials - Teams within Teams.

Langley RE, Mason MD.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):787-788. doi: 10.1016/j.clon.2017.10.001. Epub 2017 Oct 27. No abstract available.

37.

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.

Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.

J Clin Pharmacol. 2018 Mar;58(3):340-346. doi: 10.1002/jcph.1029. Epub 2017 Nov 6.

PMID:
29106714
38.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A.

J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 2017 Nov 6.

39.

North Carolina Toxic Substance Incidents Program 2010-2015: Identifying Areas for Injury Prevention Efforts.

Eiffert S, Etienne S, Hirsch A, Langley R.

Toxics. 2017 Aug 6;5(3). pii: E16. doi: 10.3390/toxics5030016.

40.

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C.

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22. No abstract available.

PMID:
28991372
41.

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.

Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P.

Clin Cancer Res. 2017 Dec 15;23(24):7543-7549. doi: 10.1158/1078-0432.CCR-16-3142. Epub 2017 Oct 2.

42.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.

Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG.

J Am Acad Dermatol. 2017 Nov;77(5):845-854.e5. doi: 10.1016/j.jaad.2017.07.013. Epub 2017 Sep 8.

43.

Staphylococcal enterotoxin-like X (SElX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors.

Langley RJ, Ting YT, Clow F, Young PG, Radcliff FJ, Choi JM, Sequeira RP, Holtfreter S, Baker H, Fraser JD.

PLoS Pathog. 2017 Sep 7;13(9):e1006549. doi: 10.1371/journal.ppat.1006549. eCollection 2017 Sep.

44.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

45.

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ.

Clin Trials. 2017 Oct;14(5):451-461. doi: 10.1177/1740774517725697. Epub 2017 Aug 22.

46.

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.

Langley RGB, Reich K, Papavassilis C, Fox T, Gong Y, Gu Ttner A.

J Drugs Dermatol. 2017 Aug 1;16(8):734-741.

PMID:
28809988
47.

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.

Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, Jiang J, Li S, Han C.

J Dermatolog Treat. 2019 Feb;30(1):27-34. doi: 10.1080/09546634.2017.1364694. Epub 2018 Sep 24.

PMID:
28797188
48.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE.

Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4.

49.

North Carolina State Agencies Working to Prevent Agricultural Injuries and Illnesses.

Langley R, Hirsch A, Cullen R, Allran J, Woody R, Bell D.

J Agromedicine. 2017;22(4):358-363. doi: 10.1080/1059924X.2017.1353468.

PMID:
28704143
50.

Fatal and non-fatal animal-related injuries and illnesses to workers, United States, 2011-2014.

Barros N, Langley R.

Am J Ind Med. 2017 Sep;60(9):776-788. doi: 10.1002/ajim.22744. Epub 2017 Jul 5.

PMID:
28677842

Supplemental Content

Loading ...
Support Center